COMPANY

Merakris Therapeutics

Company-reported stage: Phase 2 · source · Oct 12, 2026

Location: Durham, NC · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Venous Stasis Ulcer Venous Leg Ulcer Cutaneous Ulcer Diabetic Ulcer Surgical Wound Dehiscence Burns - Multiple Pressure Ulcers Mixed Ulcer Ischemic Ulcer Diabetic Foot Ulcer MTX-001 (human amniotic fluid)

3Trials (company is sponsor)

Funding and NIH signals

NIH award NIH awarded $1.11M (SBIR Phase II 1R44DK146625-01, new, notice Jul 17, 2026). NIH RePORTER 1R44DK146625-01 (Jul 17, 2026)
Evidence (1 event)
- Jul 17, 2026 · NIH RePORTER 1R44DK146625-01
  Organization: MERAKRIS THERAPEUTICS INC; City/State: HILLSBOROUGH, NC; Project number: 1R44DK146625-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1109504; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of Efficacy and Safety of MTX-001 in Diabetic Foot Ulcers; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 21, 2026 Grant Government grant announced Jul 21, 2026. Source: company's own press page. source ↗
Sep 1, 2024 Trial start Not phased (device or behavioral study): A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix source ↗
Feb 26, 2022 Trial start Phase 2: MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers source ↗

Upcoming milestones

Mar 31, 2027 (ESTIMATED) · Phase 2 · MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers · NCT04647240

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 21, 2026 Government grant announced Jul 21, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT04647240	MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers	Phase 2	Recruiting	Feb 26, 2022	Mar 31, 2027 (estimated)
NCT06730022	Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds	Not listed	Available	Not listed	Not listed
NCT06444906	A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	Sep 1, 2024	May 31, 2025 (estimated)